

# CFS®

## Chemotherapy Foundation SYMPOSIUM

# UPDATE

### Innovative Cancer Therapy for Tomorrow®

## A Message From the Chair

William K. Oh, MD

The Chemotherapy Foundation Symposium is finally here! After a year of rapid advancements and changes across all of oncology, it's once again time to gather in New York City. It's time to translate all that research and new treatment guidelines into practice.

At this point, I think it's safe to say that Chemotherapy Foundation Symposium is a bit of a misnomer. Cancer treatment is so much more than chemo. Radiation and surgery have long been mainstays in cancer treatment, but modern advancements in targeted therapies and immunoncology have become pillars in treatment as well. That's why we've renamed this historic meeting.

The Chemotherapy Foundation Symposium should reflect its inclusion of all options and all oncologists. And soon that meeting, **CFS®: Innovative Cancer Therapy for Tomorrow®**, will take place.

Each year, **CFS®** brings together hundreds of oncologists from around the globe, to deliver evidence-based and state-of-the-art education on all things cancer. This year, that tradition continues.

**CFS®** is larger than its 100 faculty and speakers, **CFS®** is more than the 25 tumor types covered, **CFS®** is longer than the 3 days we gather, and **CFS®** is more than one meeting: **CFS®** is the impact it leaves on you and your patients.

Join us this year and make **CFS®** your own.

William K. Oh, MD

Chief, Division of Hematology and Medical Oncology  
Professor of Medicine and Urology  
Icahn School of Medicine at Mount Sinai  
New York, NY  
Program Co-Chair, **CFS®**



## WHAT'S INSIDE

A message from the co-chair .....	1
Tiki Barber, keynote speaker .....	2
Can't miss satellites! .....	2
Topic's covered at this year's meeting .....	3

## JOIN US!

November 7 – 9, 2018

New York Marriott Marquis  
New York, NY

## Benefits of attending this year's CFS®!

- Network with the top minds in oncology
- Incorporate the latest clinical data into your practice
- Challenge the experts with your most difficult cases
- 100+ Experts. 25 Tumor Types. 3 Days. 1 Meeting.

For more information and to register, visit  
[gotoper.com/go/CFS18NEWS3](http://gotoper.com/go/CFS18NEWS3)

# Can't miss satellite symposia at this year's meeting!

	7 WEDNESDAY	8 THURSDAY	9 FRIDAY
9:00 AM		<b>Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer Forward</b> • 9:00 AM - 10:00 AM	
10:00 AM			
11:00 AM			
12:00 PM			
1:00 PM	<b>Medical Crossfire®: An Oncologist's Guide to Using Biosimilars in Breast Cancer: Right Patient, Right Time, Right Treatment</b> 1:40 PM - 3:10 PM	<b>Medical Crossfire®: Evaluating Immunology Strategies Across Tumor Types</b> 2:00 PM - 3:30 PM	<b>Medical Crossfire®: How Do You Use Liquid Biopsies in NSCLC?</b> • 2:10 PM - 3:40 PM
2:00 PM			
3:00 PM			
4:00 PM			
5:00 PM			
6:00 PM	<b>Bring Your Own Case (BYOC™)! Addressing Challenging Clinical Scenarios in Breast Cancer</b> 6:00 PM - 7:30 PM		
7:00 PM			

Register today and save your seat! CFS registration not required!

### Medical Crossfire®: An Oncologist's Guide to Using Biosimilars in Breast Cancer: Right Patient, Right Time, Right Treatment

Advanced testing and validation technologies have expanded the number of biosimilars approved and in development for use in breast cancer, including HER2-targeting agents. Join this midday **Medical Crossfire®** to discuss regulatory requirements, manufacturing requirements, and the latest clinical data about the use of biosimilars in breast cancer.

Learn more at [gotoper.com/go/CFSBio18](http://gotoper.com/go/CFSBio18)

### Bring Your Own Case (BYOC™)! Addressing Challenging Clinical Scenarios in Breast Cancer

Join Drs. Joyce O'Shaughnessy, Mark E. Robson, Joseph A. Sparano, and Heather L. McArthur for dinner to get the answers for your most challenging cases. This expert panel will overview the latest and most-need-to-know data as it applies to your patients. We bring the experts, you bring the case!

Learn more at [gotoper.com/go/CFSBYOC18](http://gotoper.com/go/CFSBYOC18)

### Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer Forward

Our understanding of triple-negative breast cancer (TNBC) has rapidly changed in recent years. Join us for a LIVE FILMING of this dynamic **Medical Crossfire®** panel focusing on the latest and best practices for metastatic TNBC, expert perspectives on the latest agents, including immunotherapy, and discuss what comes next.

Learn more at [gotoper.com/go/TNBC18](http://gotoper.com/go/TNBC18)

### Medical Crossfire®: Evaluating Immunology Strategies Across Tumor Types

Immune checkpoint inhibitors represent an entirely new treatment modality in the fight against cancer. By harnessing the body's own immune system to eradicate tumor cells, these therapies are transforming and improving patient outcomes across an increasingly broad range of malignancies. Join us for this live **Medical Crossfire®** as the role of I/O across multiple tumors is broken down and debated.

Learn more at [gotoper.com/go/MXIO18](http://gotoper.com/go/MXIO18)

### Medical Crossfire®: How Do You Use Liquid Biopsies in NSCLC?

Molecular testing has changed how we approach lung cancer. Liquid-based biopsies and multigene panels are exciting and new technologies, but as with any new approach questions remain. When should you use a liquid biopsy? When do you need to retest? How does circulating tumor DNA affect treatment? Join this **Medical Crossfire®** discussion led by Dr. Benjamin Levy as he and the expert panel answer the overriding question: How Do You Use Liquid Biopsies in NSCLC?

Learn more at [gotoper.com/go/CFSMXLB18](http://gotoper.com/go/CFSMXLB18)



## Tiki Barber's Family Journey with Breast Cancer

When Tiki was playing for the University of Virginia Cavaliers, his mother was diagnosed with breast cancer. Initially keeping her diagnosis a secret, Tiki's mother fought through several forms of therapy and came out on top. Now she's been cancer-free for 22 years! At **CFS®** Tiki will tell her motivational story to raise awareness and help others through the same journey his family endured.

“ **CFS®** has been putting on this conference for a long time—36 years! Greatness isn't doing something once, it's doing something over and over and over again. It's being available when people need you. ”



[gotoper.com](http://gotoper.com)

## Agenda Highlights

### Wednesday, November 07, 2018

- Myeloproliferative Neoplasms
- Myelodysplastic Syndrome
- Lymphoma
- Leukemias
- CAR T-Cell Therapy
- Multiple Myeloma
- Rare Hematologic Malignancies
- **Medical Crossfire**<sup>®</sup>: An Oncologist's Guide to Using Biosimilars in Breast Cancer: Right Patient, Right Time, Right Treatment
- Genitourinary Cancers
- Specialized CE track for nurses!
- **Bring Your Own Case (BYOC™)!** Addressing Challenging Clinical Scenarios in Breast Cancer

### Thursday, November 08, 2018

- Gynecologic Oncology
- Dermatologic Cancers
- A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer Forward
- Immunotherapy
- Giants of Cancer Care: Maurie Markman, MD
- Greenspan Lecture: David Hyman, MD
- Keynote Speaker: Tiki Barber
- **Medical Crossfire**<sup>®</sup>: Evaluating Immuno-Oncology Strategies Across Tumor Types
- Breast Cancer
- Specialized "How I Do It" Track

### Friday, November 09, 2018

- Lung Cancers
- Gastrointestinal Cancers
- **Medical Crossfire**<sup>®</sup>: How Do You Use Liquid Biopsies in NSCLC?
- Glioblastoma Multiforme
- Head, Neck, Thyroid Cancers
- Patient-Centered Care and Oncology Practice

## Program Co-Chairs



**Adam M. Brufsky, MD, PhD**  
University of Pittsburgh  
Pittsburgh, PA

**Lectures:** State-of-the-Art Neoadjuvant Approaches in Breast Cancer (Thursday); **Medical Crossfire**<sup>®</sup>: LHRH Preserves Fertility in Premenopausal Women With Early Breast Cancer (Thursday); **Medical Crossfire**<sup>®</sup>: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer Forward (Thursday)



**Benjamin Levy, MD**  
Johns Hopkins Sidney Kimmel Cancer Center  
Washington, DC

**Lectures:** **Medical Crossfire**<sup>®</sup>: Which Biomarker Is Best to Guide Clinical Decision Making With IO Therapy? PD-L1, TMB, or Nothing at All? (Friday); **Medical Crossfire**<sup>®</sup>: How Do You Use Liquid Biopsies in NSCLC? (Friday)



**William K. Oh, MD**  
Icahn School of Medicine at Mount Sinai  
New York, NY

**Lectures:** **Medical Crossfire**<sup>®</sup>: Targeted Therapy, Immunotherapy, and Chemotherapy for Advanced Bladder Cancer: What Is the Right Treatment? What Is the Right Sequence? (Wednesday)

### Steering Committee

Arjun V. Balar, MD  
Susana M. Campos, MD, MPH  
Ajai Chari, MD  
Alexander E. Drilon, MD  
Cathy Eng, MD, FACP  
Jason J. Luke, MD, FACP  
John Mascarenhas, MD

Register now to hear about all these updates and more!

[gotoper.com/go/CFS18NEWS3](http://gotoper.com/go/CFS18NEWS3)

### TWO WAYS TO REGISTER



[gotoper.com/go/CFS18DR](http://gotoper.com/go/CFS18DR)

or



1-609-378-3701

#### REGISTRATION FEES

#### ADVANCED

#### ON-SITE

REGISTRATION FEES	ADVANCED	ON-SITE
Physicians	\$599	\$699
Fellows*	\$249	\$349
Nurses, PAs, Other HCPs	\$249	\$349
Industry**	\$749	\$849

\***FELLOWS** registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

\*\***INDUSTRY** is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For any other question email us at: [info@gotoper.com](mailto:info@gotoper.com)

# CFS<sup>®</sup>

UPDATE

“ This is a can't-miss conference. I go every year! ”

Register early to guarantee yourself a seat! Hotel room block is going fast!

# 36<sup>th</sup> Annual CFS<sup>®</sup>

*Innovative Cancer Therapy for Tomorrow<sup>®</sup>*

**NOVEMBER 7 – 9, 2018**

**New York Marriott Marquis  
New York, NY**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians' Education Resource<sup>®</sup>, LLC and Pharmacy Times Continuing Education. Physicians' Education Resource<sup>®</sup>, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians' Education Resource<sup>®</sup>, LLC designates this live activity for a maximum of 26.75 AMA PRA Category 1 Credits<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource<sup>®</sup>, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 26.75 Contact Hours.



Pharmacy Times Continuing Education<sup>™</sup> is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is approved for a maximum of 22.75 contact hours (0.2275 CEUs)

under the ACPE universal activity numbers:

November 7, 2018, Conference Day 1 – 0290-9999-18-099-L01-P (7.75 contact hours)

November 8, 2018, Conference Day 2 – 0290-9999-18-100-L01-P (7.0 contact hours)

November 9, 2018, Conference Day 3 – 0290-9999-18-101-L01-P (8.0 contact hours)

The activity is available for continuing education (CE) credit through December 9, 2018.

PER<sup>®</sup> complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Exelixis, Inc., Genomic Health, Inc., Ferring Pharmaceuticals, Inc., Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Novocure, Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron, Seattle Genetics, Inc., Takeda Oncology, and Taiho Oncology, Inc

For more information and to register visit  
[gotoper.com/go/CFS18NEWS3](http://gotoper.com/go/CFS18NEWS3)

  
Physicians' Education Resource, LLC  
PER Events, LLC